PMID- 29990831
OWN - NLM
STAT- MEDLINE
DCOM- 20181214
LR  - 20211204
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 106
DP  - 2018 Oct
TI  - Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia 
      based on the regulation of URAT1 and GLUT9.
PG  - 434-442
LID - S0753-3322(17)35428-8 [pii]
LID - 10.1016/j.biopha.2018.06.163 [doi]
AB  - Fraxini Cortex (also known as Qinpi, QP) has been used for the treatment of 
      hyperuricemia with a significant difference on efficacy of QP from different 
      regions. However, it;s still unknown whether proportion of components is the key 
      and why same kind of herbs have different therapeutic effects. In this study, 
      different sources of QP were collected from Shaanxi Qinpi extracts (SQPE), Henan 
      Qinpi extracts (HQPE), Hebei Qinpi extracts (GQPE) provinces in China. Rat model 
      of hyperuricemia with hypoxanthine combined with potassium oxonate were 
      established to determine the levels of blood urea nitrogen (BUN), serum uric acid 
      (SUA), urine uric acid (UUA) and creatinine (Cr). Hematoxylin-eosin staining 
      (H&E) and Periodic Acid-Schiff staining (PAS) were performed for renal pathology 
      while Western blot analysis and real-time PCR analysis for proteins and mRNA 
      expression levels. High-performance liquid chromatograph (HPLC) was used for 
      components and composition analysis. Our results demonstrated that QPE from 
      different regions could alleviate hyperuricemia via increasing significantly the 
      SCr and BUN levels whereas decreasing markedly UCr, SUA and UUA levels. 
      Additionally, QPE could also improve the pathological changes of the kidneys. The 
      protein and mRNA levels of urate reabsorption transporter 1 (URAT1) and glucose 
      transporter 9 (GLUT9) were down-regulated by QPE treatment. SQPE hold a better 
      activity on improving hyperuricemia and regulating URAT1 and GLUT9. HPLC analysis 
      showed that the proportion of four components aesculin, aesculetin, fraxin, 
      fraxetin were 9.002: 0.350: 8.980: 0.154 (SQPE); 0.526: 0.164: 7.938: 0.102 
      (HQPE); 12.022: 1.65: 0.878: 1.064 (GQPE). These data indicate that this 
      proportion of effective components may be an important factor for efficacy of QP 
      and had implications for the treatment of hyperuricemia.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Zhou, Yuanli
AU  - Zhou Y
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 
      712046, Shaanxi, PR China; Key Laboratory of New Drug Delivery System of Chinese 
      Medical Materia, Jiangsu Provincial Academy of Chinese Medicine, Nanjing, 210028, 
      Jiangsu, PR China.
FAU - Zhang, Xuanguo
AU  - Zhang X
AD  - Shaanxi Traditional Chinese Medicine Hospital, Xi'an, 710003, Shaanxi, PR China.
FAU - Li, Chao
AU  - Li C
AD  - Key Laboratory of New Drug Delivery System of Chinese Medical Materia, Jiangsu 
      Provincial Academy of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China; 
      Jumpcan Pharmaceutical Co., Ltd, Taixing, 225400, Jiangsu, PR China.
FAU - Yuan, Xin
AU  - Yuan X
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 
      712046, Shaanxi, PR China.
FAU - Han, Lihua
AU  - Han L
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 
      712046, Shaanxi, PR China.
FAU - Li, Zheng
AU  - Li Z
AD  - College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin 
      University of Traditional Chinese Medicine, Tianjin, 300193, PR China; Tianjin 
      Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, 300193, PR China.
FAU - Tan, Xiaobin
AU  - Tan X
AD  - Key Laboratory of New Drug Delivery System of Chinese Medical Materia, Jiangsu 
      Provincial Academy of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China.
FAU - Song, Jie
AU  - Song J
AD  - Key Laboratory of New Drug Delivery System of Chinese Medical Materia, Jiangsu 
      Provincial Academy of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China.
FAU - Wang, Gang
AU  - Wang G
AD  - Key Laboratory of New Drug Delivery System of Chinese Medical Materia, Jiangsu 
      Provincial Academy of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China.
FAU - Jia, Xiaobin
AU  - Jia X
AD  - College of Chinese medicine, China Pharmaceutical University, Nanjing, Jiangsu, 
      210009, PR China.
FAU - Feng, Liang
AU  - Feng L
AD  - Jumpcan Pharmaceutical Co., Ltd, Taixing, 225400, Jiangsu, PR China; College of 
      Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, 300193, PR China; College of Chinese 
      medicine, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China; 
      College of Pharmacy, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, PR 
      China. Electronic address: wenmoxiushi@163.com.
FAU - Qiao, Xiting
AU  - Qiao X
AD  - Central Hsopital of Xianyang, Xianyang, 712000, Shaanxi, PR China. Electronic 
      address: qxting2y@126.com.
FAU - Liu, Jiping
AU  - Liu J
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 
      712046, Shaanxi, PR China. Electronic address: liwenjie780711@163.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180711
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anion Transport Proteins)
RN  - 0 (Biomarkers)
RN  - 0 (Coumarins)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (GLUT6 protein, rat)
RN  - 0 (Gout Suppressants)
RN  - 0 (Monosaccharide Transport Proteins)
RN  - 0 (Slc22a12 protein, rat)
RN  - 0 (Umbelliferones)
RN  - 1Y1L18LQAF (Esculin)
RN  - 268B43MJ25 (Uric Acid)
RN  - 3C18L6RJAZ (horse chestnut seed)
RN  - AYI8EX34EU (Creatinine)
RN  - CD3GD44O3K (fraxetin)
RN  - SM2XD6V944 (esculetin)
RN  - V7M270Y072 (fraxin)
SB  - IM
MH  - Aesculus
MH  - Animals
MH  - Anion Transport Proteins/genetics/*metabolism
MH  - Biomarkers/blood/urine
MH  - Blood Urea Nitrogen
MH  - Coumarins/analysis/pharmacology
MH  - Creatinine/urine
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation
MH  - Drugs, Chinese Herbal/analysis/*pharmacology
MH  - Esculin/analysis/pharmacology
MH  - Gout Suppressants/analysis/*pharmacology
MH  - Hyperuricemia/*drug therapy/genetics/metabolism/physiopathology
MH  - Kidney/*drug effects/metabolism/physiopathology
MH  - Male
MH  - Monosaccharide Transport Proteins/genetics/*metabolism
MH  - Rats, Sprague-Dawley
MH  - Recovery of Function
MH  - Umbelliferones/analysis/pharmacology
MH  - Uric Acid/blood/*metabolism/urine
OTO - NOTNLM
OT  - Fraxini Cortex
OT  - GLUT9
OT  - Hyperuricemia
OT  - Structural proportion of components
OT  - URAT1
EDAT- 2018/07/11 06:00
MHDA- 2018/12/15 06:00
CRDT- 2018/07/11 06:00
PHST- 2017/10/18 00:00 [received]
PHST- 2018/06/27 00:00 [revised]
PHST- 2018/06/27 00:00 [accepted]
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2018/12/15 06:00 [medline]
PHST- 2018/07/11 06:00 [entrez]
AID - S0753-3322(17)35428-8 [pii]
AID - 10.1016/j.biopha.2018.06.163 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Oct;106:434-442. doi: 10.1016/j.biopha.2018.06.163. 
      Epub 2018 Jul 11.